Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emicizumab Prophylaxis in Type 3 Von Willebrand Disease
2024-515622-80-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Jun 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, open-label trial of emicizumab in von Willebrand disease (VWD) (3 cohorts), sponsored by Roche. Primary endpoint: Number of treated bleeds over time. Planned start Jun 2025; status: authorised.
02
Drugs
emicizumab
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on 2024-515622-80-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515622-80-00.